GHK-Cu + BPC-157: BPC-157 + GHK-Cu
The efficacy of ABILIFY MAINTENA for the maintenance treatment of bipolar I disorder was established in a 52-week, double-blind, placebo-controlled, randomized withdrawal trial in adult patients who were experiencing a manic episode at trial entry, met DSM-IV-TR criteria for bipolar I disorder, and had a history of at least one previous manic or mixed episode with manic symptoms of sufficient severity to require one of the following interventions: hospitalization and/or treatment with a mood stabilizer, and/or treatment with an antipsychotic agent
doi: 10.1097/MIB.0000000000000204 26 LiuZRenZZhangJChuangCCKandaswamyEZhouTet al
Transparent Ingredients: It is always best to ask what ingredients are being mixed into your skin brightening injections
No serious systemic side effects have been documented in peer-reviewed studies at therapeutic doses
"Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial." Lancet